Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADGRE2 CAR-T in Relapsed/Refractory AML
NCT05463640Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADCLEC.syn1 CAR T cells in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoints: Changes in cytokine level after ADGRE2 CAR-T infusion up to 2 years and Change characteristics of chimeric antigen receptor(CAR)-T cell number and copy number up to 2 years. Status: unknown.
02
Drugs
ADCLEC.syn1 CAR T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05463640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463640.